If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 3 Similar Profiles
Breast Neoplasms Medicine & Life Sciences
Triple Negative Breast Neoplasms Medicine & Life Sciences
Neoadjuvant Therapy Medicine & Life Sciences
exemestane Medicine & Life Sciences
Homologous Recombination Medicine & Life Sciences
Platinum Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Mutation Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2000 2018

  • 397 Citations
  • 9 h-Index
  • 10 Article
  • 5 Review article
  • 2 Chapter

A breast multi-disciplinary genomic tumor board is feasible and can provide timely and impactful recommendations

Tsung, K., Thompson, C. L., Knight, J. M., Maximuk, S., Sadri, N., Gilmore, H. L., Keri, R. A., Vinayak, S., Harris, L. & Silverman, P., Jan 1 2018, (Accepted/In press) In : Breast Journal.

Research output: Contribution to journalArticle

Breast
Neoplasms

Genetic/familial high-risk assessment: Breast and ovarian, version 2.2017: Featured updates to the NCCN guidelines

Daly, M. B., Pilarski, R., Berry, M., Buys, S. S., Farmer, M., Friedman, S., Garber, J. E., Kauff, N. D., Khan, S., Klein, C., Kohlmann, W., Kurian, A., Litton, J. K., Madlensky, L., Merajver, S. D., Offit, K., Pal, T., Reiser, G., Shannon, K. M., Swisher, E. & 7 othersVinayak, S., Voian, N. C., Weitzel, J. N., Wick, M. J., Wiesner, G. L., Dwyer, M. & Darlow, S., Jan 1 2017, In : JNCCN Journal of the National Comprehensive Cancer Network. 15, 1, p. 9-20 12 p.

Research output: Contribution to journalReview article

Risk Management
Ovarian Neoplasms
Breast
Hereditary Neoplastic Syndromes
Guidelines
3 Citations

Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer

Telli, M. L., Hellyer, J., Audeh, W., Jensen, K. C., Bose, S., Timms, K. M., Gutin, A., Abkevich, V., Peterson, R. N., Neff, C., Hughes, E., Sangale, Z., Jones, J., Hartman, A. R., Chang, P. J., Vinayak, S., Wenstrup, R. & Ford, J. M., Dec 23 2017, (Accepted/In press) In : Breast Cancer Research and Treatment. p. 1-6 6 p.

Research output: Contribution to journalArticle

Homologous Recombination
Breast Neoplasms
Drug Therapy
Triple Negative Breast Neoplasms
Mutation
6 Citations

Interferon-beta represses cancer stem cell properties in triple-negative breast cancer

Doherty, M. R., Cheon, H. J., Junk, D. J., Vinayak, S., Varadan, V., Telli, M. L., Ford, J. M., Stark, G. S. & Jackson, M. W., Dec 26 2017, In : Proceedings of the National Academy of Sciences of the United States of America. 114, 52, p. 13792-13797 6 p.

Research output: Contribution to journalArticle

Triple Negative Breast Neoplasms
Neoplastic Stem Cells
Interferon-beta
Breast Neoplasms
Transducers
2 Citations

Role of Platinum in Early-Stage Triple-Negative Breast Cancer

La Belle, A., Khatib, J., Schiemann, W. P. & Vinayak, S., Nov 1 2017, In : Current Treatment Options in Oncology. 18, 11, 68.

Research output: Contribution to journalReview article

Triple Negative Breast Neoplasms
Platinum
Drug Therapy
Anthracyclines
Biodiversity